Tag: Intradermal Administration

Company News: ISA Pharmaceuticals Granted European Patent for the Intradermal Administration of ISA101

– Intradermal administration provides significant benefits compared to subcutaneous application

ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed immunotherapeutics against cancer and persistent viral infections, today announced it has been granted a European patent (patent no. EP 2 155 240) for the intradermal administration of synthetic long peptides (SLP®s) based on HPV oncogenes, including its lead compound ISA101.

Specifically, the patent was granted for the therapeutic use of intradermally delivered long peptides derived from the E2, E6 and/or E7 proteins of the human papillomavirus (HPV) to treat or prevent HPV-related diseases.

ISA101 is a clinical-stage immunotherapeutic for the treatment of early-stage, advanced and recurrent cancers induced by HPV16 infections and is based on ISA Pharmaceuticals´ proprietary SLP^® platform. The compound is currently in clinical Phase I/II trials in cervical cancer and anal intraepithelial neoplasia (AIN).

As shown in healthy volunteers, intradermal administration of low doses of the HPV16 E6 and E7 SLP® without any adjuvant resulted in an effective, long-lasting systemic T cell response. This shows that, compared to subcutaneous delivery, the new epidermal routing with lower doses and absence of a concomitant adjuvant is also capable of eliciting a robust immune response in naïve individuals.